YOUR SOURCE FOR HEMOPHILIA CLINICAL AND RESEARCH SOLUTIONS

Posted: June 5, 2017

FACTOR VIII

For chromogenic determination of FVIII levels in plasma and concentrates

COAMATIC® FVIII (K822585)

  • Sensitive and reproducible – measure FVIII in moderate to severe hemophilia A patients
  • Suitable to measure b-domain deleted FVIII and extended half-life recombinant replacement products
  • Suitable for monitoring new, longer acting agents
  • No need for factor deficient plasma
  • Instrument applications available
  • FDA cleared for diagnostic use

COATEST® SP FVIII (K824086)

  • Ideal for measuring FVIII concentrates
  • 1% BSA in accordance with recommendations for dilution of highly purified FVIII concentrates
  • Conforms to EP FVIII potency test requirements
  • FDA cleared for diagnostic use

COATEST® SP4 FVIII (K824094)

  • Coatest® SP FVIII factor reagent divided into 4 vials, for smaller volume testing
  • FDA cleared for diagnostic use

TECHNOCHROM FVIII:C* (5344101)

TECHNOCHROM FVIII:C FOR CEVERON® ALPHA* (5344103)

  • Excellent reagent stability, accuracy and precision
  • Four reference standards (cal. against WHO)
  • Assay range 0-200%

FVIII INHIBITOR REAGENT KIT* (5152005)

FVIII INHIBITOR REAGENT KIT HCV NEG* (5152009)

Reagent kit for the determination of Factor VIII Inihibitor according to Bethesda

  • Improved specificity in the lower range of antibody detection due to dilution with buffered normal FVIII plasma (1 IU.FVIII/ml)
  • Contains FVIII INH plasma as positive control and FVIII INH free plasma as negative control

FVIII INHIBITOR PLASMA* (5159008)

FVIII INHIBITOR PLASMA HCV NEG* (5159010)

FVIII DEFICIENT PLASMA, IMMUND.* (5154002)

FVIII DEFICIENT PLASMA, NATIVE* (5154007)

 

FACTOR IX (FIX)

Bringing chromogenic Factor IX determination into the next era

ROX FIX* (900020)

  • Highly sensitive chromogenic assay for Factor IX activity in plasma or concentrates
  • Study of new FIX variants and Hemophilia B gene therapy
    • Does not overestimate FIX activity compared to certain aPTT reagents in quantifying FIX variants
  • Reliable potency assignments of recombinant and plasma-derived FIX
  • FIX deficient plasma not required

 

Also available: vWF and FXIII assays

 

 

Questions about any product in our lineup?

The Diapharma team is just a call or click away.

800.526.5224 | diapharma.com

hemophilia clinical and research solutions
ML-00-00307Rev01 *For research use only in the US and Canada